CARDIOVASCULAR JOURNAL OF AFRICA • Volume 35, No 2, May – August 2024 AFRICA 123 22. Djuric P, Dimkovic N, Schlieper G, Djuric Z, Pantelic M, Mitrovic M, et al. Sodium thiosulphate and progression of vascular calcification in endstage renal disease patients: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transplant 2020; 35(1): 162–169. 23. Yu Y, Bi ZM, Wang Y, Chen ZQ, Xu SW. Effect of sodium thiosulfate on coronary artery calcification in maintenance hemodialysis patients. Zhonghua Yi Xue Za Zhi 2016; 96(46): 3724–3728. [Chinese]. 24. Ghiandai G, Ralli C, Imperiali P, Zingarelli A, Duranti E. Is the sodium thiosulfate therapy useful for vascular calcification in dialysis patients? G Ital Nefrol 2015; 32(3): gin/32.3.6. [Italian]. 25. Zhu XH, Chen L, Li YY. Effect of sodium thiosulfate on coronary artery calcification in maintenance hemodialysis patients and influence on hypersensitive c-reactive protein level. Dial Artif Organs 2020; 31(3): 9–14. [Chinese]. 26. Zhu XH, Li YY, Chen L, Qiu BZ. Effect of sodium thiosulfate on coronary artery calcification in maintenance hemodialysis patients China Mod Med 2019; 6(13): 105–108. [Chinese]. 27. Mao YH, Xue SQ. Risk factors of calcification in peritoneal dialysis patients and the effect of sodium thiosulfate intervention. Med Innov China 2019; 16(23): 27–32. [Chinese]. 28. Mathews SJ, de Las Fuentes L, Podaralla P, Cabellon A, Zheng S, Bierhals A, et al. Effects of sodium thiosulfate on vascular calcification in end-stage renal disease: a pilot study of feasibility, safety and efficacy. Am J Nephrol 2011; 33(2): 131–138. 29. Adirekkiat S, Sumethkul V, Ingsathit A, Domrongkitchaiporn S, Phakdeekitcharoen B, Kantachuvesiri S, et al. Sodium thiosulfate delays the progression of coronary artery calcification in haemodialysis patients. Nephrol Dial Transplant 2010; 25(6): 1923–1929. 30. Saengpanit D, Chattranukulchai P, Tumkosit M, Siribumrungwong M, Katavetin P, Sitprija V, et al. Effect of sodium thiosulfate on arterial stiffness in end-stage renal disease patients undergoing chronic hemodialysis (Sodium Thiosulfate – Hemodialysis Study): a randomized controlled trial. Nephron 2018; 139(3): 219–227. 31. Yonova DH, Vazelov ES, Trendafilov II, Stoinova VV, Nedevska MT, Antonov SA. First impressions of cardiovascular calcification treatment in hemodialysis patients with a new dialysis fluid containing sodium thiosulphate (STS). Int J Artif Organs 2014; 37(4): 308–314. 32. Messa M, Tomei P, Motton M, Ortalda V, Gangemi C, Lupo A. Effect of sodium thiosulphate on aortic calcifications in hemodialysis patients. Nephrol Dial Transplantation 2014; 29: iii48. 33. Wang SX. The effect of sodium thiosulfate for calciphylaxis in dialysis patients. Chin J Clin Rational Drug Use 2021; 14(2B): 95–97. [Chinese]. 34. Li XG. Evaluation of the effect of sodium thiosulfate on coronary artery calcification in maintenance hemodialysis patients. Chin J Prescrip Drug 2021; 19(7): 109–111. [Chinese]. 35. Bian Z, Zhang Q, Shen L, Feng Y, Chen S. The effect of sodium thiosulfate on coronary artery calcification in hemodialysis patients. Am Soc Artif Int Organs J 2022; 68(3): 402–406. 36. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6(7): e1000097. 37. Higgins J, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011 [cited 2018 Oct 10]. http:// www.handbook.cochrane.org. 38. Sterne JA, Hernan MA, Reeves BC et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Br Med J 2016; 355: i4919. 39. Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014; 19(14): 135. 40. Benz K, Hilgers KF, Daniel C, Amann K. Vascular calcification in chronic kidney disease: the role of inflammation. Int J Nephrol 2018; 13(2018): 4310379. 41. Araya CE, Fennell RS, Neiberger RE, Dharnidharka VR. Sodium thiosulfate treatment for calcific uremic arteriolopathy in children and young adults. Clin J Am Soc Nephrol 2006; 1(6): 1161–1166. 42. Shang D, Xie Q, Shang B, Zhang M, You L, Hao CM, et al. Hyperphosphatemia and hs-CRP initiate the coronary artery calcification in peritoneal dialysis patients. Biomed Res Int 2017; 2017: 2520510. 43. Pasch A, Schaffner T, Huynh-Do U, Frey BM, Frey FJ, Farese S. Sodium thiosulfate prevents vascular calcifications in uremic rats. Kidney Int 2008; 74(11): 1444–1453. 44. Lu PH, Chuo HE, Kuo KL, Liao JF, Lu PH. Clinical efficacy and safety of sodium thiosulfate in the treatment of uremic pruritus: a meta-analysis of randomized controlled trials. Toxins 2021; 13(11): 769. 45. Song YH, Wang SY, Lang JH, Xiao YF, Cai GY, Chen XM. Therapeutic effect of intravenous sodium thiosulfate for uremic pruritus in hemodialysis patients. Ren Fail 2020; 42(1): 987–993. 46. Hayden MR, Tyagi SC, Kolb L, Sowers JR, Khanna R. Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol 2005; 18(4): 4. 47. Chen NX, O’Neill K, Akl NK, Moe SM. Adipocyte induced arterial calcification is prevented with sodium thiosulfate. Biochem Biophys Res Commun 2014; 449(1): 151–156. 48. Zhong H, Liu F, Dai X, Zhou L, Fu P. Sodium thiosulfate protects human aortic smooth muscle cells from osteoblastic transdifferentiation via highlevel phosphate. Kaohsiung J Med Sci 2013; 29(11): 587–593. 49. Doneray H, Ozden A, Gurbuz K. The successful treatment of deep softtissue calcifications with topical sodium thiosulphate and acetazolamide in a boy with hyperphosphatemic familial tumoral calcinosis due to a novel mutation in FGF23. J Clin Res Pediatr Endocrinol 2022; 14(2): 239–243. 50. Mageau A, Guigonis V, Ratzimbasafy V, Bardin T, Richette P, Urena P, et al. Intravenous sodium thiosulfate for treating tumoral calcinosis associated with systemic disorders: report of four cases. Joint Bone Spine 2017; 84(3): 341–344. 51. Arabshahi B, Silverman RA, Jones OY, Rider LG. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr 2012; 160(3): 520–522. 52. Vo TM, Disthabanchong S. Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease? World J Cardiol 2014; 6(5): 216–226. 53. Baker BL, Fitzgibbons CA, Buescher LS. Calciphylaxis responding to sodium thiosulfate therapy. Arch Dermatol 2007; 143(2): 269–270. 54. Ackermann F, Levy A, Daugas E, Schartz N, Riaux A, Derancourt C, et al. Sodium thiosulfate as first-line treatment for calciphylaxis. Arch Dermatol 2007; 143(10): 1336–1337. 55. Shen C, Zhou Y, Chen Z, Rao L. Hypercalcemia associated with sodium thiosulfate treatment in a patient with calciphylaxis. Pol Arch Intern Med 2019; 129(9): 638–640. 56. Peng T, Zhuo L, Wang Y, Jun M, Li G, Wang L, et al. Systematic review of sodium thiosulfate in treating calciphylaxis in chronic kidney disease patients. Nephrology 2018; 23(7): 669–675. 57. Burja S, Jovic A, Ekart R, Piko N, Miljkovic J, Breznik V. Successful treatment of extensive uremic calciphylaxis with intravenous sodium thiosulfate and its potential in treating various diseases of pathologic calcification. Acta Dermatovenerol Alp Pannonica Adriat 2019; 28(1): 37–40. 58. Udomkarnjananun S, Kongnatthasate K, Praditpornsilpa K, Eiam-Ong S, Jaber BL, Susantitaphong P. Treatment of calciphylaxis in CKD: a systematic review and meta-analysis. Kidney Int Rep 2018; 4(2): 231–244.
RkJQdWJsaXNoZXIy NDIzNzc=